ASCO GU 2021 Bladder Cancer

REVIEW UroToday

Viewing 1-20 of 50 articles

ASCO GU 2021: Role of Definitive Local Therapy After Complete Clinical Response to Neoadjuvant Chemotherapy

ASCO GU 2021: Optimal Radiologic Assessment After Systemic Therapy for Muscle-Invasive Bladder Cancer

ASCO GU 2021: Patient Perspective on Newly Diagnosed Muscle-Invasive Bladder Cancer: What Do I Hope the Doctor Will Address?

ASCO GU 2021: First Results from the Phase 3 CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma

ASCO GU 2021: Impact of Equal Access Healthcare on Race Disparities in Bladder Cancer

ASCO GU 2021: Phase II Clinical Study of Concurrent Durvalumab and Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Localized Urothelial Cancer of Bladder: Results for Primary Analyses and Survival. BTCRC-GU15-023

ASCO GU 2021: Phase II Study of Gemcitabine and Split-Dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy (RC) in Patients with Muscle-Invasive Bladder Cancer (MIBC)

ASCO GU 2021: Uncertainties in the Timing and Sequencing of Therapies for Metastatic Disease

ASCO GU 2021: A Phase II Trial Of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy For Bladder Cancer (RETAIN BLADDER): Interim Analysis

ASCO GU 2021: Uncertainties in the Optimal Delivery of Trimodality Therapy

ASCO GU 2021: Enfortumab Vedotin in Previously Treated Urothelial Cancer - Results of EV-301 & EV-201 Cohort 2 Discussion

ASCO GU 2021: Enfortumab Vedotin In Cisplatin-Ineligible Patients with Locally Advanced Or Metastatic Urothelial Cancer Who Received Prior PD-1/PD-L1 Inhibitors: EV-201 Cohort 2

ASCO GU 2021: Primary results of EV-301: A Phase III Trial of Enfortumab Vedotin vs Chemotherapy in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

ASCO GU 2021: Radical Cystectomy for High-Risk Non-Muscle-Invasive Bladder Cancer: Who and Why?

ASCO GU 2021: SGNTUC-019: Phase II Basket Study of Tucatinib and Trastuzumab in Previously Treated Solid Tumors with HER2 Alterations: Urothelial Cancer Cohort

ASCO GU 2021: Deintensification of Management of Low-Risk Non-Muscle-Invasive Bladder Cancer

ASCO GU 2021: Socio-Environmental Conditions Associated with Geospatial Clusters of Urothelial Carcinoma: A Multi-Institutional Analysis

ASCO GU 2021: Tailored Immunotherapy Approach with Nivolumab in Advanced Transitional Cell Carcinoma (TITAN-TCC)

ASCO GU 2021: Molecular Landscape of Non-Muscle-Invasive Bladder Cancer and Subcellular Risk Factors for Progression

ASCO GU 2021: Efficacy of Chemohyperthermia in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Fail BCG Therapy

1
2
3